{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:30:54Z","timestamp":1793050254942,"version":"4.5.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/fpc.0b013e3283498131","type":"journal-article","created":{"date-parts":[[2011,7,28]],"date-time":"2011-07-28T05:43:08Z","timestamp":1311831788000},"page":"624-630","source":"Crossref","is-referenced-by-count":45,"title":["Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy"],"prefix":"10.1097","volume":"21","author":[{"given":"Mike","family":"Ufer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina","family":"von St\u00fclpnagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiltrud","family":"Muhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierk","family":"Haenisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Remmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Majed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Plischke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Stephani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolf","family":"Cascorbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210213","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.315.7113.924","article-title":"Epilepsy in childhood.","volume":"315","author":"Neville","year":"1997","journal-title":"BMJ"},{"key":"R2-2-20210213","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy.","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"R3-2-20210213","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1212\/WNL.57.12.2259","article-title":"Response to first drug trial predicts outcome in childhood temporal lobe epilepsy.","volume":"57","author":"Dlugos","year":"2001","journal-title":"Neurology"},{"key":"R4-2-20210213","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1528-1167.2005.54904.x","article-title":"Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms.","volume":"46","author":"Schmidt","year":"2005","journal-title":"Epilepsia"},{"key":"R5-2-20210213","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1528-1157.2003.42802.x","article-title":"Widespread upregulation of drug-resistance proteins in fatal human status epilepticus.","volume":"44","author":"Sisodiya","year":"2003","journal-title":"Epilepsia"},{"key":"R6-2-20210213","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs.","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol"},{"key":"R7-2-20210213","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/pgs.09.34","article-title":"Epilepsy pharmacogenetics.","volume":"10","author":"Kasperaviciute","year":"2009","journal-title":"Pharmacogenomics"},{"key":"R8-2-20210213","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1528-1167.2008.01858.x","article-title":"Polymorphism of the MDR1ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis.","volume":"50","author":"Bournissen","year":"2009","journal-title":"Epilepsia"},{"key":"R10-2-20210213","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.seizure.2010.05.004","article-title":"ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis.","volume":"19","author":"Haerian","year":"2010","journal-title":"Seizure"},{"key":"R12-2-20210213","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/j.1528-1167.2008.01661.x","article-title":"Association of ABCB1 genetic variants 3435CT and 2677GT to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients.","volume":"49","author":"Mosyagin","year":"2008","journal-title":"Epilepsia"},{"key":"R13-2-20210213","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/jpet.103.049858","article-title":"Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity.","volume":"306","author":"Potschka","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R14-2-20210213","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/sj.tpj.6500403","article-title":"Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex.","volume":"7","author":"Haenisch","year":"2007","journal-title":"Pharmacogenomics J"},{"key":"R15-2-20210213","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/tpj.2010.20","article-title":"Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function.","volume":"11","author":"Laechelt","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"R16-2-20210213","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/FPC.0b013e3282f974b7","article-title":"Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.","volume":"18","author":"Haenisch","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R17-2-20210213","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FPC.0b013e328329940b","article-title":"Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24CT polymorphism in young and adult patients with epilepsy.","volume":"19","author":"Ufer","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R18-2-20210213","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1211\/jpp.60.5.0009","article-title":"ABCC2 haplotype is not associated with drug-resistant epilepsy.","volume":"60","author":"Seo","year":"2008","journal-title":"J Pharm Pharmacol"},{"key":"R19-2-20210213","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/FPC.0b013e328338073a","article-title":"A nonsynonymous variation in MRP2ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy.","volume":"20","author":"Kim","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"R20-2-20210213","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/j.1528-1167.2009.02077.x","article-title":"Letter: lack of association between MDR1 polymorphisms and pharmacoresistance to anticonvulsive drugs in patients with childhood-onset epilepsy.","volume":"50","author":"Von Stulpnagel","year":"2009","journal-title":"Epilepsia"},{"key":"R21-2-20210213","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1046\/j.1528-1157.2001.10401.x","article-title":"A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology.","volume":"42","author":"Engel","year":"2001","journal-title":"Epilepsia"},{"key":"R22-2-20210213","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJM199601183340308","article-title":"Antiepileptic drugs.","volume":"334","author":"Brodie","year":"1996","journal-title":"N Engl J Med"},{"key":"R23-2-20210213","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1086\/379378","article-title":"A comparison of bayesian methods for haplotype reconstruction from population genotype data.","volume":"73","author":"Stephens","year":"2003","journal-title":"Am J Hum Genet"},{"key":"R24-2-20210213","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrn1728","article-title":"Drug resistance in brain diseases and the role of drug efflux transporters.","volume":"6","author":"Loscher","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"R25-2-20210213","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuropharm.2006.07.038","article-title":"Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.","volume":"52","author":"Baltes","year":"2007","journal-title":"Neuropharmacology"},{"key":"R26-2-20210213","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.neuropharm.2008.08.032","article-title":"Several major antiepileptic drugs are substrates for human P-glycoprotein.","volume":"55","author":"Luna-Tortos","year":"2008","journal-title":"Neuropharmacology"},{"key":"R27-2-20210213","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa021986","article-title":"Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.","volume":"348","author":"Siddiqui","year":"2003","journal-title":"N Engl J Med"},{"key":"R28-2-20210213","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1101\/gr.1965304","article-title":"Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene.","volume":"14","author":"Soranzo","year":"2004","journal-title":"Genome Res"},{"key":"R29-2-20210213","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1212\/01.WNL.0000141021.42763.F6","article-title":"Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy.","volume":"63","author":"Zimprich","year":"2004","journal-title":"Neurology"},{"key":"R30-2-20210213","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1248\/bpb.31.2137","article-title":"Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracilleucovorin (FOLFIRI).","volume":"31","author":"Fujita","year":"2008","journal-title":"Biol Pharm Bull"},{"key":"R31-2-20210213","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1152\/physrev.00037.2005","article-title":"Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.","volume":"86","author":"Sarkadi","year":"2006","journal-title":"Physiol Rev"},{"key":"R32-2-20210213","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/awh726","article-title":"Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study.","volume":"129","author":"Sillanpaa","year":"2006","journal-title":"Brain"},{"key":"R33-2-20210213","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eplepsyres.2003.12.008","article-title":"Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport.","volume":"58","author":"Gibbs","year":"2004","journal-title":"Epilepsy Res"},{"key":"R34-2-20210213","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.106.102491","article-title":"Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays.","volume":"320","author":"Baltes","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"R35-2-20210213","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.neuroscience.2004.07.051","article-title":"Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain.","volume":"129","author":"Nies","year":"2004","journal-title":"Neuroscience"},{"key":"R36-2-20210213","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.eplepsyres.2005.11.011","article-title":"Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis.","volume":"68","author":"Kubota","year":"2006","journal-title":"Epilepsy Res"},{"key":"R37-2-20210213","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01213011-201110000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:22:30Z","timestamp":1786047750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01213011-201110000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e3283498131","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}